Inflammation and oxidative stress caused by nitric oxide synthase uncoupling might lead to left ventricular diastolic and systolic dysfunction in patients with hypertension

Objective To investigate the role of oxidative stress, inflammation, hypercoagulability and neuroendocrine activation in the transition of hypertensive heart disease to heart failure with preserved ejection fraction (HFPEF). Methods We performed echocardiography for 112 patients (≥ 60 years old) with normal EF (18 controls and 94 with hypertension), and determined protein carbonylation (PC), and tetrahydrobiopterin (BH4), C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), fibrinogen, plasminogen activator inhibitor type-I (PAI-I), von Willebrand factor, chromogranin A (cGA) and B-type natriuretic peptide (BNP) levels from their blood samples. Results We found that 40% (38/94) of the patients with hypertension (HT) had no diastolic dysfunction (HTDD−), and 60% (56/94) had diastolic dysfunction (HTDD+). Compared to the controls, both patient groups had increased PC and BH4, TNF-α, PAI-I and BNP levels, while the HTDD+ group had elevated cGA and CRP levels. Decreased atrial and longitudinal left ventricular (LV) systolic and diastolic myocardial deformation (strain and strain rate) was demonstrated in both patient groups versus the control. Patients whose LV diastolic function deteriorated during the follow-up had elevated PC and IL-6 level compared to their own baseline values, and to the respective values of patients whose LV diastolic function remained unchanged. Oxidative stress, inflammation, BNP and PAI-I levels inversely correlated with LV systolic, diastolic and atrial function. Conclusions In patients with HT and normal EF, the most common HFPEF precursor condition, oxidative stress and inflammation may be responsible for LV systolic, diastolic and atrial dysfunction, which are important determinants of the transition of HT to HFPEF.

[1]  A. Logan,et al.  Arterial Stiffness in Hemodialysis: Which Parameter to Measure to Predict Cardiovascular Mortality? , 2009, Kidney and Blood Pressure Research.

[2]  D. Kass,et al.  Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. , 2007, Journal of the American College of Cardiology.

[3]  J. Bronzwaer,et al.  Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension , 2008, Circulation.

[4]  Casper G. Schalkwijk,et al.  Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension , 2008 .

[5]  L. d’Uscio,et al.  Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. , 2009, Trends in pharmacological sciences.

[6]  D. Fekkes,et al.  Quantitation of total biopterin and tetrahydrobiopterin in plasma. , 2007, Clinical biochemistry.

[7]  W. Paulus,et al.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. , 2011, European heart journal.

[8]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.

[9]  J. Bronzwaer,et al.  Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction , 2012, Circulation.

[10]  P. Steendijk,et al.  Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction , 2011, Circulation. Heart failure.

[11]  S. Umemura,et al.  Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. , 2012, Journal of the American College of Cardiology.

[12]  B. Sobel,et al.  Modulators of induction of plasminogen activator inhibitor type-1 in HepG2 cells by transforming growth factor-&bgr; , 2011, Coronary artery disease.

[13]  T. Fukushima,et al.  Analysis of reduced forms of biopterin in biological tissues and fluids. , 1980, Analytical biochemistry.

[14]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[15]  Yongmei Liu,et al.  Inflammatory Markers and Incident Heart Failure Risk in Older Adults: The Health, Aging, and Body Composition Study , 2009 .

[16]  E. Cirillo,et al.  Reduced Atherosclerotic Burden in Subjects With Genetically Determined Low Oxidative Stress , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[17]  Rui-ming Liu,et al.  Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. , 2008, Antioxidants & redox signaling.

[18]  D. Harrison,et al.  Uncoupled Cardiac Nitric Oxide Synthase Mediates Diastolic Dysfunction , 2010, Circulation.

[19]  M. Serafini,et al.  Oxidative stress in atherosclerosis development: the central role of LDL and oxidative burst. , 2012, Endocrine, metabolic & immune disorders drug targets.

[20]  D. Sorescu,et al.  NAD(P)H oxidase: role in cardiovascular biology and disease. , 2000, Circulation research.

[21]  D. Kass,et al.  Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. , 2005, The Journal of clinical investigation.

[22]  Paolo Salvi,et al.  Validation of a new non-invasive portable tonometer for determining arterial pressure wave and pulse wave velocity: the PulsePen device , 2004, Journal of hypertension.

[23]  K. Channon,et al.  Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology , 2010, Heart.

[24]  B. Nagy,et al.  Increased B-type natriuretic peptide levels in early-onset versus late-onset preeclampsia , 2014, Clinical chemistry and laboratory medicine.

[25]  D. MacIver Current controversies in heart failure with a preserved ejection fraction. , 2010, Future cardiology.

[26]  E. Stadtman,et al.  Carbonyl assays for determination of oxidatively modified proteins. , 1994, Methods in enzymology.

[27]  James B. Mitchell,et al.  Reversal of Cardiac Hypertrophy and Fibrosis From Pressure Overload by Tetrahydrobiopterin: Efficacy of Recoupling Nitric Oxide Synthase as a Therapeutic Strategy , 2008, Circulation.

[28]  B. Nagy,et al.  Natriuretic peptide precursor B gene (TTTC)(n) microsatellite polymorphism in pre-eclampsia. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[29]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[30]  A J Tajik,et al.  Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. , 1997, Journal of the American College of Cardiology.

[31]  W. Paulus,et al.  Molecular and Cellular Basis for Diastolic Dysfunction , 2012, Current Heart Failure Reports.

[32]  D. Phelan,et al.  Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? , 2011, European journal of heart failure.

[33]  M. Crabtree,et al.  Altered Plasma Versus Vascular Biopterins in Human Atherosclerosis Reveal Relationships Between Endothelial Nitric Oxide Synthase Coupling, Endothelial Function, and Inflammation , 2007, Circulation.

[34]  T. Münzel,et al.  Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. , 2008, Antioxidants & redox signaling.